Adding Palbociclib to Cetuximab in Platinum-Resistant Head and Neck Cancer
Novel Monoclonal Antibody Plus Cetuximab Under Study in Head/Neck Cancer
Statin Use After Radiotherapy for Head and Neck Cancer Survivors
FDA Approves Pembrolizumab in PD-L1–Expressing Squamous Cell Carcinoma of the Esophagus
Is There a Link Between Head/Neck Radiotherapy and Difficult Tracheal Intubation?
HPV16-E6 Antibody Seroconversion in Oropharyngeal Cancer
Dose De-escalation of Adjuvant Radiotherapy for HPV-Associated Oropharyngeal Cancer
Is Sentinel Lymph Node Biopsy for Select Head and Neck Cancers Cost-Effective?
Expanding Treatment Options in SCCHN: What Role Do Cancer Immunotherapies Have? (login required)
Management of Head & Neck Cancer at Disease Progression: Now What? (login required)
JADPRO Regional Lectures: Immunotherapy: Head & Neck Case Studies
Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors (login required)
Vanderbilt-Ingram Cancer Center
Fox Chase Cancer Center
University of Michigan Comprehensive Cancer Center
University of California San Diego Moores Cancer Center
Cetuximab (Head and Neck Cancers)
ThyCa: Thyroid Cancer Survivors’ Association, Inc.
NCCN Guidelines for Patients®: Thyroid Cancer
American Head & Neck Society (AHNS)